Format

Send to

Choose Destination
Int J Parasitol. 2015 Mar;45(4):203-7. doi: 10.1016/j.ijpara.2014.12.006. Epub 2015 Feb 7.

The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model.

Author information

1
Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA. Electronic address: aprahami@bu.edu.
2
Hematology and Medical Oncology Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
3
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria.
4
Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
5
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.
6
Institute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow G12 8TA, UK.

Abstract

ES-62 is an anti-inflammatory phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae. Accelerated atherosclerosis frequently occurs in systemic lupus erythematosus, resulting in substantial cardiovascular morbidity and mortality. We examined the effects of ES-62 in the gld.apoE(-/-) mouse model of this condition. Treatment with ES-62 did not substantially modulate renal pathology but caused decreased anti-nuclear autoantibody levels. Moreover, a striking 60% reduction in aortic atherosclerotic lesions was observed, with an associated decrease in macrophages and fibrosis. We believe that these latter findings constitute the first example of a defined parasitic worm product with therapeutic potential in atherosclerosis: ES-62-based drugs may represent a novel approach to control accelerated atherosclerosis in systemic lupus erythematosus.

KEYWORDS:

Atherosclerosis; ES-62; Helminth; Systemic lupus erythematosus

PMID:
25666929
PMCID:
PMC4355381
DOI:
10.1016/j.ijpara.2014.12.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center